Phase II trial of cisplatin and α-interferon in advanced malignant melanoma

Kim A. Margolin, James H. Doroshow, Steven A. Akman, Lucille A. Leong, Robert J. Morgan, George Somlo, James Raschko, Cynthia Pereira, Lisa Yonemoto, Chul Ahn

Research output: Contribution to journalArticlepeer-review

31 Scopus citations


Purpose: To evaluate the antitumor activity of combination cisplatin (CDDP) and α-interferon (α-IFN) in advanced, measurable metastatic melanoma. Patients and Methods: Adult patients with metastatic melanoma were required to have bidimensionally measurable lesions and a Karnofsky performance status ≥ 60%. Serum creatinine ≤ 1.5 mg/dL, creatinine clearance ≥ 60 mL/min, adequate organ and bone marrow function, and radiologic proof of the absence of brain metastases were required. CDDP 40 mg/m2 intravenously (IV) on day 1 and day 8, and α-IFN 3 million units/m2 subcutaneously on days 1 to 5 and 8 to 12 were administered every 3 to 4 weeks. Results: Forty-two patients were entered onto this phase II trial and were assessable for response and toxicity. Three patients achieved complete responses (CRs) that lasted 31+, 5, and 8+ months. Seven patients had partial responses (PRs) and a median response duration of 4.4 months. The overall objective response rate was 24% (95% confidence interval, 12% to 39%). Toxicities were mild. Only 11% of the courses required dose reduction of α- IFN, and three of 128 courses required CDDP dose reduction for reversible nephrotoxicity. Conclusion: The combination of moderate-dose CDDP and α-IFN as administered in this schedule is well tolerated and possesses encouraging activity in metastatic melanoma.

Original languageEnglish (US)
Pages (from-to)1574-1578
Number of pages5
JournalJournal of Clinical Oncology
Issue number10
StatePublished - Jan 1 1992

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Phase II trial of cisplatin and α-interferon in advanced malignant melanoma'. Together they form a unique fingerprint.

Cite this